ECSP066404A - Composiciones oftálmicas para el tratamiento de la hipertensión ocular - Google Patents

Composiciones oftálmicas para el tratamiento de la hipertensión ocular

Info

Publication number
ECSP066404A
ECSP066404A EC2006006404A ECSP066404A ECSP066404A EC SP066404 A ECSP066404 A EC SP066404A EC 2006006404 A EC2006006404 A EC 2006006404A EC SP066404 A ECSP066404 A EC SP066404A EC SP066404 A ECSP066404 A EC SP066404A
Authority
EC
Ecuador
Prior art keywords
sub
treatment
eye
ophthalm
compositions
Prior art date
Application number
EC2006006404A
Other languages
English (en)
Inventor
James B Doherty
Meng-Hsin Chen
Luping Liu
Swaminathan R Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP066404A publication Critical patent/ECSP066404A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a potentes compuestos bloqueantes del canal de potasio de Fórmula I o una de sus formulaciones para el tratamiento de glaucoma y otros estados patológicos que conducen a una presión intraocular elevada en el ojo de un paciente. Esta invención también se refiere al uso de dichos compuestos para proporcionar un efecto neuroprotector al ojo de especies de mamíferos, en particular de seres humanos.
EC2006006404A 2003-09-04 2006-03-01 Composiciones oftálmicas para el tratamiento de la hipertensión ocular ECSP066404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50009503P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
ECSP066404A true ECSP066404A (es) 2006-09-18

Family

ID=34312181

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006404A ECSP066404A (es) 2003-09-04 2006-03-01 Composiciones oftálmicas para el tratamiento de la hipertensión ocular

Country Status (20)

Country Link
US (1) US7410992B2 (es)
EP (1) EP1663987B1 (es)
JP (1) JP4546961B2 (es)
KR (1) KR20060090801A (es)
CN (2) CN1845904A (es)
AT (1) ATE425971T1 (es)
AU (1) AU2004272546B2 (es)
BR (1) BRPI0414102A (es)
CA (1) CA2537410C (es)
DE (1) DE602004020079D1 (es)
EC (1) ECSP066404A (es)
IL (1) IL174068A0 (es)
IS (1) IS8306A (es)
MA (1) MA28017A1 (es)
MX (1) MXPA06002515A (es)
NO (1) NO20061505L (es)
NZ (1) NZ545401A (es)
RU (1) RU2006110625A (es)
WO (1) WO2005026128A1 (es)
ZA (1) ZA200601321B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574078A1 (en) * 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP5747392B2 (ja) * 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
EP2626702A4 (en) * 2010-10-08 2014-03-26 Axis Inc DIAGNOSIS, DIAGNOSTIC PROCEDURE AND THERAPEUTIC AGENT FOR FIBROMYALGIA
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
CN110256314B (zh) * 2019-06-28 2020-12-15 南京林业大学 一种β-芳基酮类化合物的制备方法及其产品

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CA2164733A1 (en) 1993-06-08 1994-12-22 Nino Sorgente Methods and compositions for lowering intraocular pressure
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
EP1251862B1 (en) * 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
WO2003105847A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (en) * 2002-11-08 2007-07-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
WO2005025568A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension

Also Published As

Publication number Publication date
ZA200601321B (en) 2007-05-30
IS8306A (is) 2006-02-16
CN102558231A (zh) 2012-07-11
EP1663987A1 (en) 2006-06-07
DE602004020079D1 (de) 2009-04-30
NZ545401A (en) 2008-10-31
ATE425971T1 (de) 2009-04-15
AU2004272546A1 (en) 2005-03-24
CA2537410A1 (en) 2005-03-24
BRPI0414102A (pt) 2006-10-31
JP2007504233A (ja) 2007-03-01
US20070010491A1 (en) 2007-01-11
CN1845904A (zh) 2006-10-11
US7410992B2 (en) 2008-08-12
KR20060090801A (ko) 2006-08-16
MA28017A1 (fr) 2006-07-03
RU2006110625A (ru) 2006-08-10
EP1663987B1 (en) 2009-03-18
CA2537410C (en) 2009-08-11
CN102558231B (zh) 2015-05-27
AU2004272546B2 (en) 2007-10-18
WO2005026128A1 (en) 2005-03-24
MXPA06002515A (es) 2006-06-20
IL174068A0 (en) 2006-08-01
JP4546961B2 (ja) 2010-09-22
NO20061505L (no) 2006-04-27

Similar Documents

Publication Publication Date Title
AU2003207900A1 (en) Methods of treatment with selective ep4 receptor agonists
EP1467982B8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
WO2004103279A3 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
SE0302760D0 (sv) New compounds
EA200700099A1 (ru) Производные пиридина
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
SE0402925D0 (sv) Novel Compounds
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
PE20030944A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
AR056943A1 (es) DERIVADOS DE AMIDAS, ISoMEROS DE LOS MISMOS O LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS COMO EL ANTAGONISTA DEL RECEPTOR VANILOIDE Y LAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS MISMOS
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
ECSP066404A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
NO20020523L (no) Nye 2-dekarboksy-2-fosfinikoprostaglandin F-analoger
PE20060557A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas como antagonistas de los receptores trpv1
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension